AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03635190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orbital Circumferential Atherectomy
Description: Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
Study NCT01563588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietaty education, physical training, physiotherapy and SPA cares
Description: 12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
Study NCT00704249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nevirapine
Description: Full-dose nevirapine from baseline (200 mg bid).
Study NCT00704249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine
Description: Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
Study NCT03605134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: level of cardiac troponin
Description: blood test
Study NCT03605134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diastolic function assessment
Description: transthoracic echocardiography
Study NCT00978575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferricarboxymaltose
Description: Single dose of maximum 1000 mg ferricarboxymaltose intravenous
Study NCT00978575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrosulfate
Description: 200mg daily for 12 weeks
Study NCT00978575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg isotonic sodium and 2 placebo tablets daily
Study NCT00365053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT00365053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02245724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Autologous bone marrow mononuclear cell transplantation
Study NCT01084135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
Study NCT00881426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg Tablets (Sandoz GmbH)
Study NCT00881426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
Study NCT03335241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Pegylated liposomal doxorubicin
Description: Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks
Study NCT01084135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid Placebo
Description: Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
Study NCT02279589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,5
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
Study NCT04460261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Inspiratory Muscle Training
Description: Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
Study NCT02279589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23® 0,1
Description: Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
Study NCT02262273 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Colleciton of data from medical records only
Study NCT01574495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error Augmentation
Description: error augmentation for arm motor recovery in individuals with stroke
Study NCT02364271 — intervention group
Intervention type: OTHER
Intervention: Thrombolysis in myocardial infarction score
Description: An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
Study NCT02279589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13® 0,5
Description: The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197).
Study NCT03120338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Development and Wellbeing Assessment
Description: The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
Study NCT00317941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaferon/Betaseron
Description: 250ug administrated with Betaject
Study NCT00317941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif
Description: 44ug administered with Rebiject II
Study NCT00317941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaferon/Betaseron
Description: 250ug administrated with Betaject light
Study NCT02364271 — intervention group
Intervention type: BIOLOGICAL
Intervention: routine blood test for hs-cTnT
Description: Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
Study NCT02364271 — intervention group
Intervention type: OTHER
Intervention: HEART score
Description: The modified HEART score of each patient was determined retrospectively by a research assistant.
Study NCT03004677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous skin-to-skin contact
Description: Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
Study NCT03335241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
Study NCT00112437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 3 mg, once weekly for 24 months
Study NCT00112437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 10 mg, once weekly for 24 months
Study NCT00112437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 25 mg, once weekly for 24 months
Study NCT00112437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Odanacatib 50 mg, once weekly for 24 months
Study NCT00112437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study
Study NCT00112437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, two 2800 IU weekly throughout the study
Study NCT00112437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
Study NCT01949493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction
Description: Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
Study NCT01949493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
Study NCT01512368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercising
Description: A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
Study NCT01810367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX Combined With Cisplatin
Study NCT01810367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Combined With Cisplatin
Study NCT02927171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents
Description: Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
Study NCT02385695 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior Dynamic Stabilization
Study NCT02385695 — intervention group
Intervention type: PROCEDURE
Intervention: Internal Fixation and Fusion
Study NCT01347918 — intervention group
Intervention type: DEVICE
Intervention: 19F capsule
Description: Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
Study NCT01347918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: sterculia
Description: 7g of sterculia will be ingested over one week together with the normal breakfast.
Study NCT01750476 — intervention group
Intervention type: DRUG
Intervention: Mirena
Study NCT01750476 — intervention group
Intervention type: DRUG
Intervention: Oral contraception
Study NCT01750476 — intervention group
Intervention type: DRUG
Intervention: Depo-Provera
Study NCT02250040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Physiotherapy techniques that included muscle training, stretching and endurance.
Study NCT02250040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Physiotherapy techniques that included muscle training, stretching and endurance.
Study NCT02250040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Techniques based on patients' functional level were added.
Description: The added techniques aimed to improve balance and movement dissociation.
Study NCT01635933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color.
Study NCT01635933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Hydrogel contact lens with color.
Study NCT00231985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit reversal therapy
Description: Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
Study NCT00231985 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive therapy
Description: Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
Study NCT03869138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-reality based dance training
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists.
Study NCT01479790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeGiene
Description: The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
Study NCT02876224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT02876224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT00112437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
Study NCT02876224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
Study NCT02242149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Description: All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
Study NCT02242149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Diacerein
Study NCT02518178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFC Necklace
Study NCT06782204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have blood and urine samples collected 2 hours after administration.
Study NCT06782022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-Uracil
Description: Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached.
Study NCT06782022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-Fluoro-Uracil
Description: Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached.
Study NCT02518178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Reminder
Description: Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
Study NCT02518178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NFC Sticker
Description: NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
Study NCT02948192 — intervention group
Intervention type: OTHER
Intervention: Survey, Sample collection
Description: Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
Study NCT04195074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
Study NCT04195074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
Study NCT04195074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Study NCT00417612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
Study NCT00417612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill
Study NCT02749370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
Study NCT03897712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Samfilcon B Contact Lenses
Description: Contact lens
Study NCT03897712 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alden Optical HP Sphere Contact Lens
Description: Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
Study NCT03897712 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ReNu MultiPlus Lubricating and Rewetting Drops
Description: For use as needed during the study.
Study NCT03897712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus Lubricating and Rewetting Drops
Description: For use as needed during the study.
Study NCT03897712 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biotrue Multi-Purpose Solution
Description: For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
Study NCT03897712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotrue Multi-Purpose Solution
Description: For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
Study NCT02203838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: 120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.